444cc5d2-e345-43ca-8289-193072077eca
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.300
- E2F_TARGETS+0.300
- MYC_TARGETS_V1+0.300
- BILE_ACID_METABOLISM+0.200
- G2M_CHECKPOINT+0.200
- NOTCH_SIGNALING+0.200
- OXIDATIVE_PHOSPHORYLATION+0.200
- PANCREAS_BETA_CELLS+0.200
- PROTEIN_SECRETION+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- IL6_JAK_STAT3_SIGNALING-0.500
- INFLAMMATORY_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- IL2_STAT5_SIGNALING-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- COMPLEMENT-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- HYPOXIA-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-77-8154-01A-11R-2247-07 | — | cohortSQ1 | 0.854 |
| 2 | f7ddd671-b2ba-4952-918b-07ae0ea84263 | — | — | 0.853 |
| 3 | SRR2780123 | — | — | 0.851 |
| 4 | sclc2008_S40.txt | — | cohortSC | 0.834 |
| 5 | SRR12696733 | — | — | 0.832 |
| 6 | TCGA-HQ-A2OF-01A-11R-A26T-07 | — | — | 0.830 |
| 7 | MNG239 | — | — | 0.827 |
| 8 | 20110070.TNBC | — | E | 0.825 |
| 9 | BS_53M8PP88 | Ependymoma NOS | — | 0.825 |
| 10 | MNG164 | — | — | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |